Session

Primary treatment of prostate cancer: Balancing benefits and side effects

Poster Session 81

  • Location:
    Room Milan, North Hall (Level 1)
  • Chairs:
     G.M. Ahlgren, Malmö (SE)
     G. Giannarini, Udine (IT)
     R.C.N. Van Den Bergh, Amsterdam (NL)
  • Aims and objectives of this session

    The aim of this session is to discuss on oncological and functional outcomes on primary treatments for prostate cancer.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
1070
The BAUS radical prostatectomy audit 2014/2015 – an update on current practice and outcomes by centre and surgeon case volume

By: Khadhouri S.1, Miller C.1, McNeill A.2, Hounsome L.3, Fowler S.4, McGrath J.1

Institutes: 1Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, 2Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, 3Public Health England, Dept. of Public Health, London, United Kingdom, 4BAUS, Dept. of Surgery, London, United Kingdom

1071
Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis

By: Seisen T.1, Vetterlein M.1, Karabon P.1, Jindal T.1, Sood A.1, Nocera L.1, Nguyen P.2, Choueiri T.3, Trinh Q-D.4, Menon M.1, Abdollah F.1

Institutes: 1Henri Ford Hospital, Dept. of Urology, Detroit, United States of America, 2Brigham and Women Hospital, Dept. of Radiation Oncology, Boston, United States of America, 3Dana Farber Cancer Institute, Dept. of Genito-Urinary Medical Oncology, Boston, United States of America, 4Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America

1072
Oncological and functional outcomes of laparoscopic versus robot-assisted radical prostatectomy: Five years results of a prospective randomised controlled trial

By: Porpiglia F.1, Fiori C.1, Bertolo R.1, Manfredi M.1, Mele F.1, Garrou D.1, Cattaneo G.1, De Luca S.1, Passera R.2, Scarpa R.M.1

Institutes: 1San Luigi Hospital, Dept. of Urology, Turin, Italy, 2San Giovanni Battista Hospital, Dept. of Nuclear Medicine, Turin, Italy

1073
Contemporary extended pelvic lymph node dissection for prostate cancer in the UK – an analysis of national practice

By: Calleja E., Fowler S., McGrath J., Sooriakumaran P., Aning J.

Institutes: BAUS Section of Oncology, British Association of Urological Surgeons, London, United Kingdom

1075
More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes after salvage radiotherapy for rising PSA after surgery: A long-term, multi-institutional analysis

By: Fossati N.1, Karnes R.J.2, Colicchia M.2, Bossi A.3, Cozzarini C.4, Fiorino C.4, Noris Chiorda B.4, Gandaglia G.1, Dell’Oglio P.1, Wiegel T.5, Shariat S.6, Goldner G.7, Joniau S.8, Battaglia A.8, Haustermans K.9, De Meerleer G.9, Fonteyne V.10, Ost P.10, Van Poppel H.5, Montorsi F.1, Briganti A.1, Boorjian S.A.2

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, 4IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, 5University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 6Medical University of Vienna, Dept. of Urology, Vienna, Austria, 7Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, 8University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 9University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 10Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

1074
Applicability of Briganti nomogram: Is it an absolute requirement before lymph node dissection in intermediate-risk prostate cancer? Assessment of the external applicability

By: Pradere B., Roumiguié M., Sanson S., Gas J., Patard P.M., Huyghe E., Rischmann P., Gamé X., Thoulouzan M., Doumerc N., Soulié M., Beauval J.B.

Institutes: CHU Toulouse, Dept. of Urology, Toulouse, France

1076
The CPC risk calculator app: A validated tool to predict recurrence after radical prostatectomy.

By: Røder M.A.1, Berg K.D.1, Loft M.D.2, Gerds T.A.3, Ferrari M.2, Thomsen F.B.1, Gruschy L.1, Kurbegovic S.1, Rytgaard H.C.3, Kjær A.4, Brasso K.1, Iversen P.1, Brooks J.2

Institutes: 1Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, 2Stanford University Medical Center, Dept. of Urology, Stanford, United States of America, 3University of Copenhagen, Dept. of Biostatistics, Copenhagen, Denmark, 4Rigshospitalet, Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster For Molecular Imaging, Copenhagen, Denmark

1077
Obesity was associated with improved metastases-free survival after surgery in 13,667 prostate cancer patients

By: Tennstedt P.1, Salomon G.1, Tilki D.1, Budäus L.1, Pompe R.1, Leyh-Bannurah S-R.2, Haese A.1, Heinzer H.1, Huland H.1, Graefen M.1, Schiffmann J.3

Institutes: 1University Medical Center Eppendorf, Martini-Klinik, Hamburg, Germany, 2University Medical Center Eppendorf, Department of Urology, Hamburg, Germany, 3Academic Hospital Braunschweig, Department of Urology, Braunschweig, Germany

1078
Functional outcomes and complications of a multicentre series of open versus robot-assisted salvage radical prostatectomy

By: Gontero P.1, Marra G.1, Alessio P.1, Oderda M.1, Palazzetti A.1, Pisano F.1, Battaglia A.1, Munegato S.1, Frea B.1, Munoz F.2, Filippini C.3, Linares E.4, Sanchez-Salas R.4, Goonewardene S.5, Dasgupta P.5, Cahill D.5, Challacombe B.5, Popert R.5, Gillatt D.6, Persad R.6, Palou J.7, Joniau S.8, Smelzo S.9, Piechaud T.9, De La Taille A.10, Roupret M.11, Albisinni S.12, Van Velthoven R.12, Morlacco A.13, Vidit S.13, Gandaglia G.14, Mottrie A.14, Smith J.15, Fiscus G.15, Van Der Poel H.16, Tilki D.17, Karnes R.J.13

Institutes: 1San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, 2Pasini Hospital, Dept. of Radiotherapy, Aosta, Italy, 3San Giovanni Battista Hospital, Dept. of Statistics, Turin, Italy, 4Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, 5Guy’s Hospital, Dept. of Urology, London, United Kingdom, 6North Bristol NHS Foundation Trust, Dept. of Urology, Bristol, United Kingdom, 7Fundaciò Puigvert, Dept. of Urology, Barcelona, Spain, 8Leuven University Hospitals, Dept. of Urology, Leuven, Belgium, 9Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, 10CHU Mondor, Dept. of Urology, Créteil, France, 11Pitié Salpétrière Hospital- University Paris 6, Dept. of Urology, Paris, France, 12Institut Jules Bordet, Université Libre De Bruxelles,, Dept. of Urology, Brussels, Belgium, 13Mayo Clinic, Dept. of Urology, Rochester, United States of America, 14OLV Hospital, Dept. of Urology, Aalst, Belgium, 15Vanderbilt University, Medical Center North, Dept. of Urology, Nashville, United States of America, 16Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 17Martini Klinik, Dept. of Urology, Hamburg, Germany

1079
Impact of type of radical prostatectomy on outcomes reported by men with prostate cancer 18 months post-diagnosis: Results from the English National Prostate Cancer Audit (NPCA)

By: Nossiter J.1, Sujenthiran A.2, Charman S.3, Cathcart P.4, Aggarwal A.3, Payne H.5, Clarke N.6, Van Der Meulen J.7

Institutes: 1Royal College Of Surgeons Of England, Dept.t of Clinical Effectiveness, London, United Kingdom, 2Royal College Of Surgeons Of England, Dept. of Clinical Effectiveness, London, United Kingdom, 3London School of Hygiene and Tropical Medicine, Dept. of Health Services Research & Policy, London, United Kingdom, 4Guy’s and St Thomas’ Hospital, NHS Foundation Trust, London, United Kingdom, 5University College London Hospitals, London NHS Foundation Trust, London, United Kingdom, 6The Christie and Salford Royal NHS Foundation Trusts, NHS Foundation Trusts, London, United Kingdom, 7 London School of Hygiene and Tropical Medicine, Dept. of Health Services Research & Policy, London, United Kingdom

1081
Randomized study evaluating postoperative outcomes in patients with complex anastomosis during da Vinci prostatectomy

By: Pushkar D., Kolontarev K., Govorov A., Rasner P.

Institutes: Moscow State Medico Stomatological University, Hospital 50, Dept. of Urology, Moscow, Russia

1082
Surgical expertise is the major determinant of decreased complication rates in contemporary patients treated with robot-assisted radical prostatectomy

By: Dell’Oglio P.1, Stabile A.1, Zaffuto E.1, Gandaglia G.1, Fossati N.1, Bandini M.1, Moschini M.1, Fallara G.1, Dehò F.1, Guazzoni G.2, Gallina A.1, Suardi N.1, Gaboardi F.1, Montorsi F.1, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Humanitas Clinical and Research Center, Dept. of Urology, Milan, Italy

1083
Characterization of the “one-pad patient” at long-term follow-up after radical prostatectomy

By: Löppenberg B., Müller G., Bach P., Von Bodman C., Brock M., Roghmann F., Noldus J., Palisaar J.

Institutes: Ruhr-University Bochum, Marien Hospital Herne, Dept. of Urology, Herne, Germany